NCT06865339 2026-04-13
TRIPL
Montefiore Medical Center
Phase 2 Recruiting
Clinical Trials
34 trialsNCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07388771 2026-03-19
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Tongji Hospital
Recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07169552 2025-12-17
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
HC Biopharma Inc.
Phase 2 Recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT07181499 2025-09-30
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07198217 2025-09-30
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06864624 2025-07-25
WU-KONG20
Tang-Du Hospital
Phase 2 Recruiting
NCT07085182 2025-07-25
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06754644 2025-06-10
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06940401 2025-05-14
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Recruiting
NCT05994131 2025-04-30
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06457789 2025-04-02
iRelate
Amsterdam UMC, location VUmc
Phase NA Recruiting
NCT06714708 2025-02-10
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT06807307 2025-02-04
KEAPnes
Regina Elena Cancer Institute
Recruiting
NCT06532591 2024-12-20
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting
NCT05991193 2024-09-20
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Recruiting
NCT05222087 2024-08-15
PRIME_LUNG
Peter MacCallum Cancer Centre, Australia
Phase 1 Recruiting
NCT05987345 2024-07-22
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
Energenx Medical LTD.
Phase NA Recruiting
NCT04712877 2024-07-17
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
Lung Cancer Mutation Consortium
Recruiting
NCT06362980 2024-07-10
EGFR
National Cancer Center, China
Phase 1 Recruiting
NCT06479759 2024-06-28
ACCLAIM
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06424821 2024-05-22
LungCadX
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05615142 2024-04-17
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Sichuan University
Phase 1 Recruiting
NCT05382728 2024-01-30
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
TYK Medicines, Inc
Phase 3 Recruiting
NCT05991206 2023-12-27
A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC
Hunan Province Tumor Hospital
Recruiting
NCT05999214 2023-09-25
99mTc-H7ND SPECT/CT Imaging in NSCLC
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Recruiting
NCT05286957 2023-03-17
Seagull
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT04720339 2022-11-23
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
University Hospital, Strasbourg, France
Phase NA Recruiting
NCT02354274 2022-04-25
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®
Odense University Hospital
Phase NA Recruiting